<p><em><strong>新网站预计将进一步加速患者入组，目前在第三阶段研究中已超过 50% 入组率，并支持未来的临床项目</strong></em></p>
<p><em><strong>GelrinC 将通过现成的再生产品改变软骨修复市场</strong></em></p>
<p>Regentis Biomaterials Ltd.（&#34;Regentis&#34;或&#34;公司&#34;）（纽约证券交易所代码：RGNT），是一家专注于创新组织修复解决方案的再生医学公司，今天宣布扩大其美国临床站点网络，进一步加强其基础设施，以支持其正在进行的 GelrinC®膝关节软骨修复的关键第三阶段研究以及未来的临床项目。</p>
<p>&#34;在我们现有的临床合作基础上，我们正在向我们的网络中增加几家新的、备受推崇的学术和临床骨科中心，&#34;Regentis 执行主席 Ehud Geller 博士表示。&#34;此次扩展旨在进一步加速患者入组，提高我们的临床策略效率，利用领先的骨科专业知识，并生成强有力的临床数据，以支持产品开发和公司近期首次公开募股后的未来商业化努力。&#34;</p>
<p>GelrinC®已在欧盟获得膝关节软骨修复的批准，目前在关键的 FDA 试验中处于中期阶段，旨在满足美国每年超过 470,000 个潜在病例的市场需求。</p>
<p>扩展的临床站点网络汇集了在软骨修复、关节保护和运动医学方面具有丰富经验的领先骨科外科医生和机构，确保高质量的临床执行和数据生成。</p>
<p>新增的参与临床站点包括：</p>
<p><strong>纽约大学朗格尼医学中心骨科与运动医学，</strong> 纽约，纽约</p>
<p>一家世界级的学术骨科中心，始终被评为美国顶尖项目之一，以外科卓越和创新而闻名。Laith Jazrawi 博士是软骨修复和关节保护领域的权威，拥有丰富的学术领导和临床试验经验。</p>
<p><strong>俄亥俄州立大学韦克斯纳医学中心，</strong> 哥伦布，俄亥俄州</p>
<p>一家顶尖的学术健康系统，拥有高容量的骨科部门和强大的转化研究能力。David Flanigan 博士是一位国际公认的外科医生 - 科学家，专注于膝关节重建和软骨修复。</p>
<p><strong>辛辛那提大学医学中心，</strong> 辛辛那提，俄亥俄州</p>
<p>一家受人尊敬的学术医疗中心，将先进的骨科护理与以结果为导向的研究相结合。Brian Grawe 博士以其在软骨保护和严格的临床研究方法方面的专业知识而闻名。</p>
<p><strong>洛约拉医学骨科，</strong> 梅伍德，伊利诺伊州</p>
<p>一个强调关节保护创新的学术临床项目，并参与多中心临床研究。John Miller 博士在软骨和半月板病理方面提供深厚的临床见解。</p>
<p><strong>杜兰大学医学院 - 骨科，</strong> 新奥尔良，路易斯安那州</p>
<p>一家享有盛誉的学术机构，拥有悠久的影响力肌肉骨骼研究和跨学科合作的历史，提供强大的学术深度和研究基础设施。</p>
<p><strong>北卡罗来纳大学骨科，</strong> 查佩尔希尔，北卡罗来纳州</p>
<p>一家全国公认的学术骨科部门，专注于临床研究和结果科学。Joe Hart 教授在肌肉骨骼研究和关节保护研究方面具有领导力。</p>
<p><strong>拉什大学医学中心，</strong> 芝加哥，伊利诺伊州</p>
<p>一家顶级学术医疗中心，以骨科创新和循证护理而广受认可。Adam Yanke 博士是软骨再生和膝关节保护领域的领先专家，贡献了外科和研究的卓越。</p>
<p><strong>关于 GelrinC</strong></p>
<p>Regentis 的主打产品 GelrinC®是一种无细胞、现成的水凝胶，具有同步侵蚀和可吸收的植入物，用于治疗膝关节软骨的疼痛损伤。作为一种创新的再生医学产品，GelrinC 提供了一种前所未有的解决方案，使外科医生和支付方能够使用现成的、简单易行、可靠且具有成本效益的程序，为患者提供一次 10 分钟的手术，快速恢复，持续缓解疼痛，并在临床研究结果的基础上实现超过 4 年的功能改善。目前市场上没有有效的现成、可用的膝关节软骨缺损治疗方案。GelrinC 已在欧盟获得 CE 标志批准，并正在进行关键的美国食品和药物管理局（FDA）研究，目前已完成超过 50% 的入组。</p>
<p><strong>关于 Regentis Biomaterials</strong></p>
<p>Regentis Biomaterials Ltd 是一家致力于开发创新组织修复解决方案的再生医学公司，旨在恢复健康并提高生活质量。Regentis 最初专注于骨科治疗，其 Gelrin 平台技术基于同步、可降解的水凝胶植入物，能够再生受损或患病的组织，包括发炎的软骨和骨骼。Regentis 的主打产品 GelrinC 是一种无细胞、现成的水凝胶，在膝关节中被侵蚀和吸收，允许周围细胞以受控和同步的方式再生软骨。GelrinC 旨在满足美国每年约 470,000 个膝关节软骨修复病例的市场需求，目前没有现成的治疗方案可用。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 “前瞻性声明”，这些声明面临重大风险和不确定性。本新闻稿中包含的所有声明，除了历史事实的陈述外，均为前瞻性声明。本新闻稿中的前瞻性声明可以通过使用诸如 “预期”、“相信”、“考虑”、“可能”、“估计”、“期望”、“打算”、“寻求”、“或许”、“计划”、“潜在”、“预测”、“项目”、“目标”、“旨在”、“应该”、“将会”、“会” 等词语或这些词语的否定形式或其他类似表达来识别，尽管并非所有前瞻性声明都包含这些词语，并包括对公司临床站点网络扩展的信念。前瞻性声明基于 Regentis 当前的预期，并受到固有的不确定性、风险和假设的影响，这些因素难以预测。此外，某些前瞻性声明基于对未来事件的假设，这些假设可能并不准确。可能影响未来结果并导致这些前瞻性声明不准确的因素包括但不限于：我们的临床试验能否证明 GelrinC 或任何未来产品候选者的安全性和有效性，以及其他积极结果；我们前期研究和临床试验的时间安排和重点，以及这些研究和试验的数据报告；GelrinC 或任何未来产品候选者的市场机会规模，包括我们对患有我们所针对疾病的患者数量的估计；我们准确识别产品候选者需求的能力；现有或可能出现的竞争疗法的成功；我们产品候选者的有益特性、安全性、有效性和治疗效果；我们获得 GelrinC 或任何未来产品候选者的 FDA 批准并获得和维持监管批准的能力；我们获得医疗界和第三方支付方对 GelrinC 或任何未来产品候选者的市场接受度的能力；我们关于进一步开发 GelrinC 或任何未来产品候选者的计划，包括我们可能追求的其他疾病状态或适应症；美国及其他地区现有的法规和监管发展；我们获得或保护知识产权的计划和能力，包括在可用情况下延长专利期限的能力，以及我们避免侵犯他人知识产权的能力；需要招聘额外人员以及我们吸引和留住这些人员的能力；我们对费用、未来收入、资本需求和额外融资需求的估计；我们对第三方的依赖；我们的财务表现及偿还贷款和债务的能力；以及我们在任何合作、许可或其他安排中谈判有利条款的能力，以及履行我们在此类合作中的义务。有关影响 Regentis 的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于在与 SEC 提交的公开发行最终招股说明书中详细列出的 “风险因素” 部分。此公告中包含的前瞻性声明截至本日期作出，Regentis 不承担更新此类信息的义务，除非适用法律要求。</p>
<p><strong>联系方式：</strong></p>
<p><strong>acarlquist@medicavp.com</strong></p>
<p><strong>来源：</strong> Regentis Biomaterials Ltd</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMTIyNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMTIyNg"/></p>

RGNT

<p>Regentis Biomaterials Ltd. 正在扩大其在美国的临床试验网络，以进行 GelrinC® 的关键性第三阶段研究，这是一种用于膝关节软骨修复的水凝胶。此次扩展包括多个领先的骨科中心，以增强患者招募，当前招募人数已超过 50%。GelrinC® 已在欧盟获得批准，旨在满足美国每年超过 470,000 个潜在病例的市场需求。新站点将利用在软骨修复方面的专业知识，并支持 Regentis 最近上市后的未来临床项目</p>

<p><em><strong>New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programs</strong></em></p>
<div class="lb-trans"><p><em><strong>新网站预计将进一步加速患者入组，目前在第三阶段研究中已超过 50% 入组率，并支持未来的临床项目</strong></em></p>
</div><p><em><strong>GelrinC is set to transform cartilage repair market with off-the-shelf regenerative products</strong></em></p>
<div class="lb-trans"><p><em><strong>GelrinC 将通过现成的再生产品改变软骨修复市场</strong></em></p>
</div><p>Regentis Biomaterials Ltd., (&#34;Regentis&#34; or the &#34;Company&#34;) (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the expansion of its U.S. clinical site network, further strengthening its infrastructure to support its ongoing pivotal Phase III study of GelrinC® for knee cartilage repair as well as future clinical programs.</p>
<div class="lb-trans"><p>Regentis Biomaterials Ltd.（&#34;Regentis&#34;或&#34;公司&#34;）（纽约证券交易所代码：RGNT），是一家专注于创新组织修复解决方案的再生医学公司，今天宣布扩大其美国临床站点网络，进一步加强其基础设施，以支持其正在进行的 GelrinC®膝关节软骨修复的关键第三阶段研究以及未来的临床项目。</p>
</div><p>&#34;Building on our existing clinical collaborations, we are adding several new, highly regarded academic and clinical orthopedic centers to our network,&#34; stated Dr. Ehud Geller, Executive Chairman of Regentis. &#34;This expansion is designed to further accelerate patient enrollment, increase the efficiency of our clinical strategy, leverage leading orthopedic expertise, and generate robust clinical data to support product development and future commercialization efforts following our company's recent IPO.&#34;</p>
<div class="lb-trans"><p>&#34;在我们现有的临床合作基础上，我们正在向我们的网络中增加几家新的、备受推崇的学术和临床骨科中心，&#34;Regentis 执行主席 Ehud Geller 博士表示。&#34;此次扩展旨在进一步加速患者入组，提高我们的临床策略效率，利用领先的骨科专业知识，并生成强有力的临床数据，以支持产品开发和公司近期首次公开募股后的未来商业化努力。&#34;</p>
</div><p>GelrinC® is approved for knee cartilage repair in the European Union and is currently at midpoint in a pivotal FDA trial for the same indication to address a U.S. market of more than 470,000 potential cases annually.</p>
<div class="lb-trans"><p>GelrinC®已在欧盟获得膝关节软骨修复的批准，目前在关键的 FDA 试验中处于中期阶段，旨在满足美国每年超过 470,000 个潜在病例的市场需求。</p>
</div><p>The expanded clinical site network brings together leading orthopedic surgeons and institutions with strong experience in cartilage repair, joint preservation, and sports medicine, ensuring high-quality clinical execution and data generation.</p>
<div class="lb-trans"><p>扩展的临床站点网络汇集了在软骨修复、关节保护和运动医学方面具有丰富经验的领先骨科外科医生和机构，确保高质量的临床执行和数据生成。</p>
</div><p>Among the Participating Clinical Sites Being Added Are:</p>
<div class="lb-trans"><p>新增的参与临床站点包括：</p>
</div><p><strong>NYU Langone Orthopedic &amp; Sports Medicine,</strong> New York, NY</p>
<div class="lb-trans"><p><strong>纽约大学朗格尼医学中心骨科与运动医学，</strong> 纽约，纽约</p>
</div><p>A world-class academic orthopedic center consistently ranked among the top programs in the United States, known for surgical excellence and innovation. Dr. Laith Jazrawi is a leading authority in cartilage repair and joint preservation, bringing extensive academic leadership and clinical trial experience.</p>
<div class="lb-trans"><p>一家世界级的学术骨科中心，始终被评为美国顶尖项目之一，以外科卓越和创新而闻名。Laith Jazrawi 博士是软骨修复和关节保护领域的权威，拥有丰富的学术领导和临床试验经验。</p>
</div><p><strong>The Ohio State University Wexner Medical Center,</strong> Columbus, OH</p>
<div class="lb-trans"><p><strong>俄亥俄州立大学韦克斯纳医学中心，</strong> 哥伦布，俄亥俄州</p>
</div><p>A premier academic health system with a high-volume orthopedic department and strong translational research capabilities. Dr. David Flanigan is an internationally recognized surgeon-scientist specializing in knee reconstruction and cartilage restoration.</p>
<div class="lb-trans"><p>一家顶尖的学术健康系统，拥有高容量的骨科部门和强大的转化研究能力。David Flanigan 博士是一位国际公认的外科医生 - 科学家，专注于膝关节重建和软骨修复。</p>
</div><p><strong>University of Cincinnati Medical Center</strong>, Cincinnati, OH</p>
<div class="lb-trans"><p><strong>辛辛那提大学医学中心，</strong> 辛辛那提，俄亥俄州</p>
</div><p>A respected academic medical center integrating advanced orthopedic care with outcomes-driven research. Dr. Brian Grawe is known for his expertise in cartilage preservation and rigorous clinical research methodology.</p>
<div class="lb-trans"><p>一家受人尊敬的学术医疗中心，将先进的骨科护理与以结果为导向的研究相结合。Brian Grawe 博士以其在软骨保护和严格的临床研究方法方面的专业知识而闻名。</p>
</div><p><strong>Loyola Medicine Orthopedic</strong>, Maywood, IL</p>
<div class="lb-trans"><p><strong>洛约拉医学骨科，</strong> 梅伍德，伊利诺伊州</p>
</div><p>An academic clinical program emphasizing innovation in joint preservation and participation in multicenter clinical studies. Dr. John Miller contributes deep clinical insight in cartilage and meniscal pathology.</p>
<div class="lb-trans"><p>一个强调关节保护创新的学术临床项目，并参与多中心临床研究。John Miller 博士在软骨和半月板病理方面提供深厚的临床见解。</p>
</div><p><strong>Tulane University School of Medicine - Orthopedics</strong>, New Orleans, LA</p>
<div class="lb-trans"><p><strong>杜兰大学医学院 - 骨科，</strong> 新奥尔良，路易斯安那州</p>
</div><p>A distinguished academic institution with a long history of impactful musculoskeletal research and interdisciplinary collaboration, providing strong academic depth and research infrastructure.</p>
<div class="lb-trans"><p>一家享有盛誉的学术机构，拥有悠久的影响力肌肉骨骼研究和跨学科合作的历史，提供强大的学术深度和研究基础设施。</p>
</div><p><strong>UNC Orthopedics, University of North Carolina</strong>, Chapel Hill, NC</p>
<div class="lb-trans"><p><strong>北卡罗来纳大学骨科，</strong> 查佩尔希尔，北卡罗来纳州</p>
</div><p>A nationally recognized academic orthopedic department with a strong focus on clinical research and outcomes science. Prof. Joe Hart brings leadership in musculoskeletal research and experience in joint preservation studies.</p>
<div class="lb-trans"><p>一家全国公认的学术骨科部门，专注于临床研究和结果科学。Joe Hart 教授在肌肉骨骼研究和关节保护研究方面具有领导力。</p>
</div><p><strong>Rush University Medical Center</strong>, Chicago, IL</p>
<div class="lb-trans"><p><strong>拉什大学医学中心，</strong> 芝加哥，伊利诺伊州</p>
</div><p>A top-tier academic medical center widely recognized for orthopedic innovation and evidence-based care. Dr. Adam Yanke is a leading expert in cartilage regeneration and knee preservation, contributing both surgical and research excellence.</p>
<div class="lb-trans"><p>一家顶级学术医疗中心，以骨科创新和循证护理而广受认可。Adam Yanke 博士是软骨再生和膝关节保护领域的领先专家，贡献了外科和研究的卓越。</p>
</div><p><strong>About GelrinC</strong></p>
<div class="lb-trans"><p><strong>关于 GelrinC</strong></p>
</div><p>Regentis' lead product, GelrinC®, is a cell-free, off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. As an innovative regenerative medical product, GelrinC offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. No effective off-the-shelf, ready to use treatment for focal knee cartilage defects is currently available on the market. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.</p>
<div class="lb-trans"><p>Regentis 的主打产品 GelrinC®是一种无细胞、现成的水凝胶，具有同步侵蚀和可吸收的植入物，用于治疗膝关节软骨的疼痛损伤。作为一种创新的再生医学产品，GelrinC 提供了一种前所未有的解决方案，使外科医生和支付方能够使用现成的、简单易行、可靠且具有成本效益的程序，为患者提供一次 10 分钟的手术，快速恢复，持续缓解疼痛，并在临床研究结果的基础上实现超过 4 年的功能改善。目前市场上没有有效的现成、可用的膝关节软骨缺损治疗方案。GelrinC 已在欧盟获得 CE 标志批准，并正在进行关键的美国食品和药物管理局（FDA）研究，目前已完成超过 50% 的入组。</p>
</div><p><strong>About Regentis Biomaterials</strong></p>
<div class="lb-trans"><p><strong>关于 Regentis Biomaterials</strong></p>
</div><p>Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.</p>
<div class="lb-trans"><p>Regentis Biomaterials Ltd 是一家致力于开发创新组织修复解决方案的再生医学公司，旨在恢复健康并提高生活质量。Regentis 最初专注于骨科治疗，其 Gelrin 平台技术基于同步、可降解的水凝胶植入物，能够再生受损或患病的组织，包括发炎的软骨和骨骼。Regentis 的主打产品 GelrinC 是一种无细胞、现成的水凝胶，在膝关节中被侵蚀和吸收，允许周围细胞以受控和同步的方式再生软骨。GelrinC 旨在满足美国每年约 470,000 个膝关节软骨修复病例的市场需求，目前没有现成的治疗方案可用。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains &#34;forward-looking statements&#34; that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;contemplate,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;seek,&#34; &#34;may,&#34; &#34;might,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;target,&#34; &#34;aim,&#34; &#34;should,&#34; &#34;will&#34; &#34;would,&#34; or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include beliefs regarding the expansion of the Company's clinical site network. Forward-looking statements are based on Regentis' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the ability of our clinical trials to demonstrate safety and efficacy of GelrinC or any future product candidate, and other positive results; the timing and focus of our preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for of GelrinC or any future product candidate, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to accurately identify demand for product candidates; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain FDA approval for of GelrinC or any future product candidate and obtain and maintain regulatory approval; our ability to obtain market acceptance of of GelrinC or any future product candidate from the medical community and third-party payors; our plans relating to the further development of GelrinC or any future product candidate, including additional disease states or indications we may pursue; existing regulations and regulatory developments in the United States and other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our dependence on third parties; our financial performance and our ability to repay our loans and debts; and our ability to negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission (&#34;SEC&#34;), including, but not limited to, the risks detailed in the section titled &#34;Risk Factors&#34; in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含 “前瞻性声明”，这些声明面临重大风险和不确定性。本新闻稿中包含的所有声明，除了历史事实的陈述外，均为前瞻性声明。本新闻稿中的前瞻性声明可以通过使用诸如 “预期”、“相信”、“考虑”、“可能”、“估计”、“期望”、“打算”、“寻求”、“或许”、“计划”、“潜在”、“预测”、“项目”、“目标”、“旨在”、“应该”、“将会”、“会” 等词语或这些词语的否定形式或其他类似表达来识别，尽管并非所有前瞻性声明都包含这些词语，并包括对公司临床站点网络扩展的信念。前瞻性声明基于 Regentis 当前的预期，并受到固有的不确定性、风险和假设的影响，这些因素难以预测。此外，某些前瞻性声明基于对未来事件的假设，这些假设可能并不准确。可能影响未来结果并导致这些前瞻性声明不准确的因素包括但不限于：我们的临床试验能否证明 GelrinC 或任何未来产品候选者的安全性和有效性，以及其他积极结果；我们前期研究和临床试验的时间安排和重点，以及这些研究和试验的数据报告；GelrinC 或任何未来产品候选者的市场机会规模，包括我们对患有我们所针对疾病的患者数量的估计；我们准确识别产品候选者需求的能力；现有或可能出现的竞争疗法的成功；我们产品候选者的有益特性、安全性、有效性和治疗效果；我们获得 GelrinC 或任何未来产品候选者的 FDA 批准并获得和维持监管批准的能力；我们获得医疗界和第三方支付方对 GelrinC 或任何未来产品候选者的市场接受度的能力；我们关于进一步开发 GelrinC 或任何未来产品候选者的计划，包括我们可能追求的其他疾病状态或适应症；美国及其他地区现有的法规和监管发展；我们获得或保护知识产权的计划和能力，包括在可用情况下延长专利期限的能力，以及我们避免侵犯他人知识产权的能力；需要招聘额外人员以及我们吸引和留住这些人员的能力；我们对费用、未来收入、资本需求和额外融资需求的估计；我们对第三方的依赖；我们的财务表现及偿还贷款和债务的能力；以及我们在任何合作、许可或其他安排中谈判有利条款的能力，以及履行我们在此类合作中的义务。有关影响 Regentis 的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于在与 SEC 提交的公开发行最终招股说明书中详细列出的 “风险因素” 部分。此公告中包含的前瞻性声明截至本日期作出，Regentis 不承担更新此类信息的义务，除非适用法律要求。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>acarlquist@medicavp.com</strong></p>
<div class="lb-trans"><p><strong>acarlquist@medicavp.com</strong></p>
</div><p><strong>SOURCE:</strong> Regentis Biomaterials Ltd</p>
<div class="lb-trans"><p><strong>来源：</strong> Regentis Biomaterials Ltd</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMTIyNg" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1131226"/></p>

Regentis 正在扩展其关键的 III 期 GelrinC 临床试验站点网络：在美国增加多个顶尖骨科中心 | RGNT 股票新闻